Advances in studies on Rotigotine transdermal patch

Rotigotine transdermal patch is the first transdermal non-ergot dopamine agonist,which is a selective dopamine D1/D2/D3 receptor agonist.Rotigotine patch is effective over 24 h providing a continuous dopaminergic stimulation in patients with Parkinson's disease(PD) and is approved for use in treatment of PD by the FDA and EMA.This paper is a review of current status of Rotigotine transdermal patch.